16
Featured Session · 16 of 35
Fatty Liver Disease (MASH)
MASH management has been transformed by resmetirom approval. Sessions cover non-invasive scoring (FibroScan, FAST, MEFIB), resmetirom real-world adoption, GLP-1 in MASH, multi-agonist trials, and the screening pathway in primary care.
Topics covered in this session
- Resmetirom adoption
- FibroScan and FAST score
- GLP-1 in MASH
- Multi-agonist trials
- MASH cirrhosis management
- MASH-HCC surveillance
Other Sessions
Explore the full GCGD 2027 program
- 01Inflammatory Bowel Disease
- 02Hepatology & Liver Disease
- 03Endoscopy & Interventional GI
- 04GI Oncology
- 05Functional GI & Motility
- 06Gut Microbiome
- 07Pediatric Gastroenterology
- 08Nutrition & Celiac Disease
- 09AI in GI
- 10Eosinophilic Esophagitis
- 11Gastric & Esophageal Cancer
- 12Pancreatic Disease
- 13Biliary & Liver Surgery
- 14Therapeutic Endoscopy
- 15Bariatric & Metabolic Endoscopy
- 17Viral Hepatitis
- 18GI Bleeding
- 19Diverticular Disease
- 20Colon Polyps & Screening
- 21Helicobacter pylori
- 22GERD & Reflux Disease
- 23Achalasia & Motility
- 24Anorectal Disorders
- 25Small Bowel Disease
- 26Mesenteric Disease
- 27IBS & Functional Pain
- 28Cystic Fibrosis & GI
- 29Geriatric GI
- 30Women's GI Health
- 31Tropical GI Disease
- 32Liver Transplantation
- 33GI Imaging
- 34Capsule Endoscopy
- 35Health Equity in GI